FDA Strikes at Yet Another Birth Tissue Company

(MedPage Today) -- The FDA is again clamping down on unapproved stem cell therapies, this time with a warning letter expressing safety and regulatory compliance concerns involving umbilical cord cellular products marketed by Regenative Labs of...
Source: MedPage Today Public Health - Category: American Health Source Type: news